Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Housing: The Most Critical Future Issue for Youth – Yet Many Feel Anxiety and Stress

- Owning a nice home tops the wish list over exploring the world or starting a family Nearly 9 out of 10 young people consider having a nice home in the future as important. Meanwhile, 6 out of 10 find the housing situation in Sweden to be entirely unreasonable and believe that their personal finances and mental health would be affected if they struggle to secure housing in the future. These are some of the insights from a new survey by Ungdomsbarometern, conducted on behalf of Mäklarsamfundet and Hemnet, presented during Almedalsveckan.  “Youth dream strongly of owning their own home,

Imfinzi improved EFS and OS in bladder cancer

25 June 2024 Imfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial First immunotherapy regimen before and aftersurgery to extend survival in bladder cancer Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca's Imfinzi(durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary

Augmentum Fintech plc Annual Report 2024

25 June 2024 Augmentum Fintech plc Annual Financial Report for the year ended 31 March 2024     Augmentum Fintech plc (LSE: AUGM) (the "Company" or "Augmentum"), Europe's leading publicly listed fintech fund, announces its audited Annual Results for the year ended 31 March 2024.  Financial highlights   · NAV before performance fee increased by 3.1% to £303.3 million1 (31 March 2023: £294.1 million1) of which the value of the investment portfolio was £265.1 million (31 March 2023: £254.3 million). · NAV per share after performance fee increased by 5.4% to 167.4p2

Wärtsilä renews its partnership with ONEE for the maintenance of two power plants in Morocco

Wärtsilä Corporation, Trade press release, 25 June 2024 at 9 AM EESTTechnology group Wärtsilä has signed a five-year Maintenance Agreement covering 169,5 MW of power generation for two Moroccan power plants. The plants are owned and operated by the Office National de l’Electricité et de l’Eau potable (ONEE), Morocco‘s public utility in charge of the production, transport and distribution of electricity. This agreement is a renewal of a previous five-year contract for the power plants in Tan Tan and Dakhla, in southern Morocco. Each of these two emergency plants operates with Wärtsilä 46

ASSA ABLOY acquires Wesko Locks in Canada

ASSA ABLOY has acquired Wesko Locks Ltd, a Canadian manufacturer and supplier of electronic and specialty locks. "I am very pleased to welcome Wesko Locks into the ASSA ABLOY Group. This acquisition delivers on our strategy to strengthen our position in mature markets through adding complementary products and solutions to our core business,” says Nico Delvaux, President and CEO of ASSA ABLOY. "Wesko Locks has an extensive portfolio that complements our current high-security products and solutions,” says Lucas Boselli, Executive Vice President of ASSA ABLOY and Head of the Americas

Stayble Therapeutics presents positive interim data from the ongoing phase Ib study with STA363

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the Company's phase Ib study has reached the follow-up goal of at least 18 patients completing their three-month visit. A total of 24 patients completed the visit. All essential data for evaluating the study's primary parameters have thus been secured. The company also presents positive interim data with established safety and tolerability (primary study objective) when evaluating available blinded data from the three-month follow-up. The patients will be followed until they complete their six-month visit. Then, the

Lundbeck and Otsuka announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD)

· The supplemental new drug application (sNDA) for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD) has been accepted and filed by the FDA · The FDA target date (PDUFA date) for completion of the review is 8 February 2025 · If approved, brexpiprazole and sertraline combination treatment would be the first FDA-approved pharmacological treatment for PTSD in more than 20 years  Valby, Denmark, 25 June 2024 – H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce the U.S. Food and Drug

Observe Medical ASA: Ex. Subsequent Offering today

OBSRV – EX. SUBSEQUENT OFFERING TODAY Issuer name: Observe Medical ASA Ex. date: 25 June 2024 Type of corporate action: Subsequent offering/repair issue Additional information: Reference is made to the stock exchange announcement published by Observe Medical ASA on 24 June 2024 with key information relating to the subsequent offering.   This information is published in accordance with the requirements of the Continuing Obligations.

Instabee adds 4,000 square metres with Wihlborgs in Helsingborg

The logistics company Instabee has signed an agreement for an additional 4,000 square metres at the Rubinen 8 property in the Ättekulla industrial area in Helsingborg.Instabee, which includes the consumer brands Budbee and Instabox, offers deliveries either to consumers’ homes or to a parcel locker. Instabee operates in six countries and can be selected as a shipping alternative with the majority of the major online retailers in Sweden. Instabee has been a tenant of Wihlborgs since 2018, when it leased 220 square metres at Berga. Since 2021, the company has been leasing 2,000 square

Neogap granted Chinese patent for innovative method of MS treatment and diagnosis

Neogap Therapeutics, a Swedish biotechnology company specialising in the development of personalised immunotherapy, has been granted a patent in China for an innovative method that opens new possibilities in the treatment and diagnosis of multiple sclerosis (MS). The patent, which complements a previously granted patent in Australia, strengthens Neogap's global presence in the field, the company's strategic intellectual property portfolio, and its ongoing research into autoimmune diseases such as MS.The patent covers a tolerogenic treatment method for multiple sclerosis (MS) using specially

Skanska signs contract with MARTA in Georgia, USA, worth USD 49M, about SEK 500M

Skanska has signed an initial contract with MARTA, Metropolitan Atlanta Rapid Transit Authority, to deconstruct the MARTA Five Points Station canopy in Atlanta, Georgia. The contract is worth USD 49M, about SEK 500M, which will be included in the second quarter of 2024.The contract includes deconstruction of the existing pre-stressed concrete canopy and demolition of the plaza to make way for a new mass timber, open-concept canopy with new pedestrian entrances. Five Points Station is the largest and busiest rail station in the MARTA system, and the connecting point for all rail lines and

Circio´s leading position in circular RNA therapeutics highlighted by broad recent coverage in international life science industry media

· Circio´s position as a pioneering player in the rapidly emerging circular RNA field is being recognized in the industry · Five articles and interviews have recently been published in widely read EU and US life science publications with a combined readership of over 3 million · Additional high-profile interviews are expected to generate further coverage in the coming monthsOslo, Norway, 25 June 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy, today announces that it has initiated a systematic

Skanska divests courthouse building in Växjö, Sweden for about SEK 490M

Skanska divests a court building in Växjö, where the Swedish Courts Administration is a tenant, for approximately SEK 490M. The transaction will be recorded by Skanska Commercial Development in the second quarter of 2024. Transfer of ownership and payment of the purchase price will take place in connection with the completion of the court, which is planned for the fourth quarter of 2026.The court is developed by Skanska in collaboration with Vacse. The building is being constructed by Skanska Sweden and is included in the order intake for the second quarter, 2024. The investment, including

SINDI: En ny standard för social hållbarhet inom fastighetsbranschen

Stockholm 2024-06-25Brunswick Real Estate (”Brunswick”), Infostat och Ramboll Management Consulting lanserar idag SINDI, Social Index for Improvement – en digitalt plattform som gör det möjligt för fastighetsbolag att mäta, följa upp och jämföra sitt sociala hållbarhetsarbete. Ambitionen med SINDI är att etablera en standard för social hållbarhet inom fastighetsbranschen.SINDI samlar expertis från Brunswick inom fastighetsinvesteringar och social hållbarhet, Infostats avancerade dataanalyser, samt Rambolls omfattande erfarenhet och kompetens inom rådgivning kopplat till social hållbarhet

Blue World completes successful testing of 200 kW maritime fuel cell system to run on green methanol

With a successful test of the first ever 200 kW HT PEM fuel cell system, an important milestone was reached in bringing new technology into play to push forward the decarbonisation of the maritime industry.[200 kW fuel cell system is tested at Blue Worlds test facilities in connection to the fuel cell factory in Aalborg Denmark] 200 kW fuel cell system is tested at Blue World's test facilities in connection to the fuel cell factory in Aalborg, Denmark     Aalborg, Denmark, 25 June 2024 – After months of preparation, Blue World Technologies is proud to announce the successful

Diös divests properties for SEK 452 milllion

Diös divests 10 properties in five cities including housing, light industry, commerce and offices. This is done through three different transactions, which take place in line with the company's strategy. The total leasable area of the divested the properties correspond to approximately 57,000 square meters and the total sales price amounts to SEK 452 MSEK. One of the divested properties, Målaren 3 in Borlänge. The buyers of the properties are NP3 Fastigheter AB, LF Norrbotten and Hagabacken Fastigheters AB. The total rental value corresponds to SEK 53.4 million and the

Gaming Innovation Group - Notification of changes in major shareholdings

MJ Foundation Fundacja Rodzinna, a company related to Mateusz Juroszek, primary insider and Board Member of Gaming Innovation Group Inc. (GiG), has today agreed to purchase 6,069,375 shares in GiG at a price of SEK 27.00 per share on 24.06.2024, ref. also separate announcement regarding mandatory notification of trade today. After the transaction, MJ Foundation holds 11,088,810 shares, representing approximately 8,24% of the total registered share capital and voting rights in GiG.  After the above transaction, Juroszek Family through MJ Foundation, ZJ Foundation, Betplay Capital Sp. z o.

Gaming Innovation Group - Mandatory notification of trade

MJ Foundation Fundacja Rodzinna, a company related to Mateusz Juroszek, primary insider and Board Member of Gaming Innovation Group Inc. (GiG), has agreed to purchase 6,069,375 shares in GiG at a price of SEK 27.00 per share on 24.06.2024. After this transaction close associates of Mateusz Juroszek own 27,652,927 shares in GiG. Betplay Capital Foundation, a company related to Tomasz Juroszek, primary insider and Board Member of GiG Platform & Sportsbook, has agreed to purchase 1,348,750 shares in GiG at a price of SEK 27.00 per share on 24.06.2024. After this transaction, close

Observe Medical ASA: Key information relating to subsequent offering _ repair issue

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 24 June 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) earlier today, regarding the placement of a private placement (the "Private

Observe Medical ASA: Disclosure of share lending by persons closely associated with primary insiders and mandatory notification of trade

Oslo, 24 June 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) earlier today (the "Announcement"), regarding the private placement of new shares in the Company (the "Private Placement"). As further described in the Announcement, the Private Placement consists of two tranches, of which tranche 1 comprises 38,137,038 offer shares ("Tranche 1") and tranche 2 comprises 16,862,962 offer shares ("Tranche 2"), the latter subject to a resolution by the extraordinary general meeting of the Company to issue

Observe Medical ASA: Potential equity investment from the group's largest partner within manufacturing and supply of urine measurement products

Oslo, 24 June 2024 Reference is made to the announcement made by Observe Medical ASA (the "Company" or "Observe Medical", and, together with its subsidiaries, the "Group", OSE ticker "OBSRV") earlier today, on 24 June 2024, regarding the successfully placed private placement of new shares in the Company to raise gross proceeds of NOK 22 million (the "Private Placement"). The Company is in this respect pleased to announce that Jiangsu Hongxin Medical Technology Co., Ltd ("Jiangsu Hongxin"), the Group's largest partner within the manufacturing and supply of urine measurement products,

Observe Medical ASA: Placement of NOK 22 million Private Placement and contemplated Subsequent Offering

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 24 June 2024 Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSRV") today announces that the Company has successfully placed a private placement of NOK 22 million with a group of existing shareholders,

Sileon has resolved on the previously announced rights issue of approximately SEK 57 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO SECTION “IMPORTANT INFORMATION” BELOW.The board of directors of Sileon AB (publ) ("Sileon" or the "Company") has, with the support of the authorization from the extraordinary general meeting on 19 June 2024, resolved on a new

Read original
There are no items matching the current filter
There are no more items matching the current filter
Back to top